are expected in 2026 AbbVie and REGENXBIO will plan the Phase 3 clinical program of investigational ABBV-RGX-314 in diabetic retinopathy (DR) ABBV-RGX-314 in Wet Age-Related Macular Degeneration ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback